Compare NSPR & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | XTNT |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 68.9M |
| IPO Year | 2009 | 2009 |
| Metric | NSPR | XTNT |
|---|---|---|
| Price | $1.35 | $0.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | $1.00 |
| AVG Volume (30 Days) | 44.7K | ★ 183.7K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | N/A | ★ 0.03 |
| Revenue | $2,310,000.00 | ★ $53,337,000.00 |
| Revenue This Year | $57.98 | N/A |
| Revenue Next Year | $95.41 | $9.30 |
| P/E Ratio | ★ N/A | $15.89 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.28 | $0.39 |
| 52 Week High | $2.93 | $0.95 |
| Indicator | NSPR | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 44.42 |
| Support Level | N/A | $0.44 |
| Resistance Level | $2.50 | $0.68 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 11.11 | 49.67 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.